What question did this study set out to answer?

To assess the eligibility and enrollment rates of transgender women within clinical trials testing pre-exposure prophylaxis (PrEP) efficacy.

November 28, 2014AIDS Care

Inclusion of trans women in pre-exposure prophylaxis trials: a review

View Full Paper

Ask AI

Bookmark

Authors

DEDaniel J. EscuderoWashington University in St. Louis TKThomas KerrNorthwestern University DODon OperarioDepartment of Health

Discussion

Member takes

Implication

Review finds trans women represented only 0.2% of participants across HIV pre-exposure prophylaxis trials, highlighting the need for targeted implementation and observational studies.

Key Points

To assess the eligibility and enrollment rates of transgender women within clinical trials testing pre-exposure prophylaxis (PrEP) efficacy.
Reviewed seven clinical trials assessing PrEP efficacy to determine eligibility criteria and enrollment proportions for transgender women.
Transgender women accounted for only 1.2% of participants in a single trial and represented just 0.2% of total enrollments across all seven trials.
Observational and feasibility studies examining social barriers—including transphobia, violence, and discrimination—are identified as the primary research priority rather than additional efficacy trials.

Cite This Study

Escudero et al. (2014) studied this question.

synapsesocial.com/papers/6a73e6260375516f85f1626e https://doi.org/10.1080/09540121.2014.986051

View Full Paper

Ask AI

Bookmark

Implication

Review finds trans women represented only 0.2% of participants across HIV pre-exposure prophylaxis trials, highlighting the need for targeted implementation and observational studies.

Inclusion of trans women in pre-exposure prophylaxis trials: a review

Discussion

Member takes

Implication

Key Points

Cite This Study

Inclusion of trans women in pre-exposure prophylaxis trials: a review

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider